samedan logo
 
 
spacer
home > ict > winter 2018 > perfect platform
PUBLICATIONS
International Clinical Trials

Perfect Platform

“Today, 47 million people live with dementia worldwide, more than the population of Spain. This number is projected to increase to more than 131 million by 2050, as populations age. Dementia also has a huge economic impact. The total estimated worldwide cost of dementia is US$818 billion, and it will become a trillion dollar disease by 2018” (1).

Because of the social impact of this chronic neurodegenerative disease, it has become a major target for new therapies and, together with Parkinson’s, accounts for approximately a third of all neurological trials initiated over the past five years (2). Despite this, the success of new medicines in the area is poor. At present, the only products on the market are Cholinesterase inhibitors and N-methyl-D-asparate (NMDA) antagonists, providing symptomatic therapy. Consequently, the drive for diseasemodifying treatments is huge, and, despite major setbacks for drugs in trials to date, in 2016, 51 Alzheimer’s trials were initiated compared to five in 2002 (3,4). Dominantly Inherited Alzheimer Network Trial (DIAN-TU) represents a new frontier for assessing the impact of disease-modifying drugs as it targets patients with a genetic predisposition and starts treatment prophylactically.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Graham Wylie has more than 25 years’ experience in the pharma industry working for Pfizer, PAREXEL, and Healthcare at Home. He was also named as one of the most influential leaders in the pharma industry by PharmaVOICE 100 in 2014. Graham joined Healthcare at Home in 2005 to set up their trial division and led the management buy out to create MRN in 2006.
spacer
Graham Wylie
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Denny Bros Group continues its support of Packaging Innovations

A world leading print company is preparing to showcase its renowned labelling and printing solutions at next month’s prestigious Packaging Innovations show.
More info >>

White Papers

PhlexEarchive: The Right Solution for Electronic Archiving of TMF Content

Phlexglobal Ltd

Many sponsor organizations have already recognized the value of moving from paper to electronic Trial Master Files (eTMFs). But few sponsors have taken a more holistic approach to the TMF lifecycle and looked at the entire process from study start-up through archiving of the TMF in electronic format, also known as e-archiving. The recurring value of managing, tracking, maintaining and accessing electronic files should not stop at the point of archiving. All of the challenges of managing an active paper TMF carry through to a paper archive. All of the benefits of an electronic TMF also carry through to the electronic archive. As companies look to move their compliance assets to secure, long-term storage, it is important to consider ongoing compliance requirements, security, accessibility, efficiency and costs of archiving TMF content in a digital format.
More info >>

 
Industry Events

LogiPharma Europe 2018

10-12 April 2018, Montreux Music & Convention Centre

Now in it’s 18th successful year, LogiPharma is the largest global end-to-end supply chain event for pharma supply chain leaders, their teams and service partners.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement